Association of Autofluorescent Advanced Glycation End Products (AGEs) with Frailty Components in Chronic Kidney Disease (CKD): Data from a Single-Center Cohort Study

Cells. 2023 Jan 29;12(3):438. doi: 10.3390/cells12030438.

Abstract

Background: Chronic kidney disease (CKD) is characterized by an overproduction and accumulation of advanced glycation end products (AGEs). Because AGEs may play a role in the development of malnutrition and sarcopenia, two essential components of frailty, we evaluated whether they may also contribute to the onset of frailty in CKD patients.

Methods: We performed a cross-sectional analysis of 117 patients. AGEs were quantified using a fluorescence spectrophotometer and soluble receptor for AGE (sRAGE) isoforms by ELISA. We defined frailty according to the frailty phenotype (FP) proposed by Fried.

Results: The average age of patients was 80 ± 11 years, 70% were male, and the mean eGFR was 25 + 11 mL/min/1.73m2. Frailty was diagnosed in 51 patients, and 40 patients were classified as pre-frail. AGEs and RAGE isoforms seem not to correlate with overall frailty. Instead, AGEs were associated with specific frailty domains, inversely associated with BMI (R = -0.22, p = 0.016) and directly associated with gait test time (R = 0.17, p = 0.049). AGEs were also associated with involuntary weight loss (OR 1.84 p = 0.027), independent of age and sex.

Conclusions: AGEs are associated with some pivotal components of the frailty phenotype, although they are not associated with frailty overall.

Keywords: advanced glycation end products (AGEs); chronic kidney disease (CKD); cleaved RAGE (cRAGE); endogenous secretory RAGE (esRAGE); frailty; soluble receptor for AGE (sRAGE).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • Frailty*
  • Glycation End Products, Advanced
  • Humans
  • Male
  • Protein Isoforms
  • Receptor for Advanced Glycation End Products / genetics
  • Renal Insufficiency, Chronic*

Substances

  • Receptor for Advanced Glycation End Products
  • Glycation End Products, Advanced
  • Protein Isoforms

Grants and funding

This study was funded by Italian Ministry of Health—Current research IRCCS.